I'm back in 1990

Chapter 782: Major Achievements

That evening, Yu Xiang told her husband something.

"Xiao Chuan, did you know? Sister Xie's team has made a breakthrough in the field of oncology drugs!"

Hearing this, Huang Xiaochuan, who was flipping through the newspaper, put it down in surprise: "There's been progress?"

Upon hearing this news, Huang Xiaochuan couldn't help but sigh in his heart, "It really wasn't easy!" Four years have passed in the blink of an eye. In these four years, the Kerui Pharmaceutical R&D Center has risen from the ground in Dapu Science Park and become a modern pharmaceutical R&D institution with world-class equipment.

Xie Xinyue not only assembled a core R&D team, but also established professional collaborations with dozens of top medical universities in mainland China and local universities in Hong Kong.

All of this is based on massive financial support. Over the past four years, the Corey Pharmaceuticals R&D Center, this money-devouring behemoth, has consumed more than three billion US dollars.

This is also the only subsidiary of Dadao Group with huge losses. Every year when the annual financial report comes out, Cao Charlie would buzz around in front of Huang Xiaochuan like a mosquito, trying to reduce the financial investment in the Kerui Pharmaceutical R&D Center. Unfortunately, Huang Xiaochuan never adopted his suggestions. As long as Xie Xinyue needed it, he would still provide strong support. Huang Xiaochuan refused to believe that so much money would be poured in without any results.

Now that the long-awaited "resounding" has finally arrived, how could Huang Xiaochuan not be overjoyed!

He immediately urged Yu Xiang, "Tell me all about it!"

Seeing the man's expression, Yu Xiang couldn't help but laugh and said, "Sister Xie and her team have developed a targeted inhibitor for specific gene mutations in hematologic malignancies, mainly certain types of acute lymphoblastic leukemia and some lymphoma classifications. According to the preclinical research data Sister Xie gave me, the drug's effects in inhibiting tumor growth and inducing cancer cell apoptosis in animal models far exceed those of similar drugs currently under development internationally, and it is also very effective in some cases that have developed drug resistance."

Huang Xiaochuan asked, "What about drug safety?" Huang Xiaochuan had a general understanding of several key aspects of drug development.

Yu Xiang, speaking from a doctor's perspective, explained to Huang Xiaochuan: "I've reviewed it. The preclinical virological assessment is excellent, with a wide therapeutic window. This means that at an effective dose, the damage to normal cells is negligible, and the expected side effects are far less than with traditional chemotherapy. To put it simply, chemotherapy and previous drugs for treating this type of disease are like killing a thousand enemies while losing eight hundred of your own. While killing cancer cells, a large number of normal cells are also killed, causing significant problems for the patient's prognosis. The therapeutic effect of this drug is very different from previous drugs. It's like a precise sniper, aiming only at killing cancer cells and rarely harming normal cells."

At this point, Yu Xiang paused for a moment, then said solemnly, "It can be said that this new drug can completely cure certain types of lymphoma and acute lymphoblastic leukemia."

Huang Xiaochuan nodded, indicating that he understood. He was very gratified. Four years had passed, and more than 3 billion US dollars had been spent. Now, he finally saw the dawn of victory.

He was also well aware of how much effort Xie Xinyue and her team had put in over the past four years.

But then he asked, "So what's the next step?"

Yu Xiang was naturally very familiar with this. She said, "The next step is to bring this drug out of the laboratory and use it on patients, which is commonly known as a clinical trial. Clinical trials are the final test to verify the safety and efficacy of a drug. In particular, Phase I and Phase II clinical trials require the most advanced and standardized medical platforms to execute and monitor them. Fortunately, Ruijin Hospital and Kangci Hospital have very strong research capabilities in the field of hematological malignancy treatment and fully meet the requirements of international clinical trial quality management standards. Therefore, Sister Xie plans to conduct Phase I and Phase II clinical trials simultaneously at Kangci and Ruijin Hospitals."

I've also spoken with Sister Xie, and we at Kangci will take the lead and fully assist Kerui Pharmaceuticals in this clinical trial, striving to bring this new targeted drug to market as soon as possible so that patients can receive good treatment and recover quickly.

Before I came back, I had made all the arrangements. I set up a dedicated team in the hematology department of Kangci Hospital to be in charge of the clinical trial. Sister Xie is also applying for clinical trials of the new drug. Once the application is approved, this work can begin.

Sister Xie will be coming to Shanghai soon, mainly to discuss a clinical trial collaboration with Ruijin Hospital. I'll ask my supervisor to put in a good word for her and try to finalize the collaboration as soon as possible.

When Huang Xiaochuan learned that Xie Xinyue was coming to Shanghai soon, he said excitedly, "It's been a while since I've seen Sister Xie. I must treat her to a meal this time and treat her well. She has really worked hard."

Huang Xiaochuan knew that if successful, it would be no less significant than detonating an atomic bomb, and the world's medical community would be shocked.

The next day, as soon as Huang Xiaochuan arrived at his office, he called Xie Xinyue.

"Congratulations, Sister Xie!"

Xie Xinyue's cheerful voice came through the phone: "Haha, your Yu Xiang already told you! But now is not the time to congratulate me. You can congratulate me after the clinical trials are completed."

Huang Xiaochuan insisted, "No, no, no, the future is the future, and the present is the present. No one knows better than me how hard it was for you to achieve what you have today."

Upon hearing this, Xie Xinyue on the other end of the phone fell silent instantly. At this moment, she was no longer the strong woman she usually was; her eyes were filled with tears.

Yes! More than 1,400 days and nights! Constant failures, constant restarting of experiments, that kind of tedious and monotonous research day after day is torture for researchers, especially when they feel they are about to make progress and breakthroughs, but instead get failures. That feeling of dejection can drive a person crazy.

Xie Xinyue is only in her forties, but two-thirds of her hair has already turned white, which shows how much pressure she is under. Without a strong heart, she definitely wouldn't have made it this far.

Perhaps it was luck, or perhaps it was the massive amount of money invested, but finally the clouds parted and the moon shone through. Xie Xinyue and her team made significant progress in targeted cancer drugs.

She choked up as she expressed her gratitude to Huang Xiaochuan: "Thank you! Thank you, Xiaochuan."

Huang Xiaochuan quickly comforted Xie Xinyue: "My dear Sister Xie! Please don't be like this. This is a joyous occasion, we should be happy, why are you crying!"

Xie Xinyue wiped away her tears: "I'm crying tears of joy."

"Hahaha!" Huang Xiaochuan laughed, then said, "I heard from Yu Xiang that you're coming to Shanghai soon. I'll be waiting for you there. When you arrive, I want to treat you to a meal. I'll cook it myself, how about it?"

Hearing this, Xie Xinyue burst into laughter through her tears: "Oh? Then I definitely have to try it! I've never eaten food cooked by Asia's richest man before!"

"Haha! I can make it anytime you want to eat it."